This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Health Policy  • Complementary and Alternative Medicine  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We have several concerns about the Editorial by Drs DeAngelis and Fontanarosa¹ regarding the regulation of dietary supplements.

There is no substantiation of the claim by DeAngelis and Fontanarosa that postmarketing regulation by the US Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) presents a "real danger" to the public. Their assertion that the "onus is on FDA to demonstrate" a lack of safety is only partially true. "New dietary ingredients" are marketed following approval of safety files by the FDA. We believe that existing food ingredients and supplements are safe based on years of uneventful human ingestion. Furthermore, the Dietary Supplement Health and Education Act (DSHEA) grants the right to take action if a supplement poses "an imminent hazard to public health" or "presents a significant or unreasonable risk of illness or injury."

Drugs and supplements are subject to premarketing as well as . . . [Full Text of this Article]

Joy Joseph, MBA; David Kropp, BS; David Madsen, PhD; Steven Yannicelli, PhD, RD
Pharmavite LLC
Northridge, Calif

RELATED ARTICLES

Regulation of Dietary Supplements—Reply
Catherine D. DeAngelis and Phil B. Fontanarosa
JAMA. 2004;291(5):560.
EXTRACT | FULL TEXT  

Drugs Alias Dietary Supplements
Catherine D. DeAngelis and Phil B. Fontanarosa
JAMA. 2003;290(11):1519-1520.
EXTRACT | FULL TEXT